1307.4000 16.10 (1.25%)
NSE Jul 04, 2025 15:31 PM
Volume: 1.5M
 

BOB Capital Markets Ltd.
Dr Reddy's (DRRD) has announced a key settlement of the patent litigation with Celgene for US Revlimid (lenalidomide capsules) used to treat multiple myeloma.
Dr. Reddy's Laborato.. has an average target of 1343.25 from 9 brokers.
More from Dr. Reddy's Laboratories Ltd.
Recommended